McKinsey Exec On Pharma's Digital Shift, Deal-Making Expectations
Executive Summary
McKinsey India's head of pharmaceutical and healthcare practice shares insights on pharma’s risk management efforts and accelerated deployment of digital technologies, including augmented reality headsets for shop floor operators amid the pandemic. He expects a broad surge in deal-making and says pharma is poised for a “full recovery” soon.
You may also be interested in...
Bayer Execs On Digital Acceleration, Getting The Building Blocks Right
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal
The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.
Amazon Pharmacy Starting Up In India: What Pharma Could Gain Or Lose
Amazon Pharmacy’s debut in India could recalibrate and disrupt drug dispensing and distribution in the country, while also tempering investment flow in the e-pharmacy segment. Some experts also predict a squeeze on pharma’s profits.
Need a specific report? 1000+ reports available
Buy Reports